For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Morgan Stanley (MS) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Watch · Gem Score +17 (−100…+100 Quality+Value blend) · Quality 64 · Value -21 · Sentiment -15 (timing only, not weighted) · Composite fair value $295.10 vs $210.55 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Morgan Stanley
MS NYSEMorgan Stanley is an American multinational investment bank and financial services company headquartered at 1585 Broadway in Midtown Manhattan, New York City. The firm operates through three primary business segments: Institutional Securities, Wealth Management, and Investment Management. Institutional Securities offers investment banking services including capital raising, mergers and acquisitions advisory, restructurings, real estate and project finance, as well as corporate lending, equities, and fixed income trading. Wealth Management provides brokerage, investment advisory, financial and wealth planning services primarily to high-net-worth individuals, along with banking, retirement plan services, and annuity and insurance products through platforms like E*Trade. Investment Management delivers asset management products and services across equity, fixed income, alternatives, real estate, and private equity to institutional and retail clients via various distribution channels. Morgan Stanley serves corporations, governments, institutions, and individuals worldwide, playing a key role in global capital markets by advising, originating, trading, managing, and distributing capital.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 10.21
Total Equity: $112.65B
Shares: 1,651,420,176
Total Debt: $341.68B
Cash: $111.70B
EBITDA: N/A
Total Debt: $341.68B
Cash: $111.70B
Revenue: $65.97B
Revenue: $65.97B
Revenue: $65.97B
Total Equity: $112.65B
Tax Rate: 22.5%
Equity: $112.65B
Total Debt: $341.68B
Cash: $111.70B
Current Liabilities: N/A
Long-Term Debt: $341.68B
Total Debt: $341.68B
Total Equity: $112.65B
Shares: 1,651,420,176
Shares: 1,651,420,176
CapEx: $0.00
Shares: 1,651,420,176
Stock Price: $210.55
Net Income: $16.86B
Industry Benchmarks
Income Statement (Annual)
Last updated: Jul 31, 2026 4:56am (23d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $56.4B | $50.2B | $50.7B | $57.6B | $66.0B |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | $25.3B | $24.0B | $25.1B | $27.1B | $30.2B |
| Operating Income | — | — | — | — | — |
| Net Income | $15.0B | $11.0B | $9.1B | $13.4B | $16.9B |
| EBITDA | — | — | — | — | — |
| EPS | $8.16 | $6.23 | $5.24 | $8.04 | $10.32 |
| EPS (Diluted) | $8.03 | $6.15 | $5.18 | $7.95 | $10.21 |
Balance Sheet (Annual)
Last updated: Jul 31, 2026 9:08am (23d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $127.7B | $128.1B | $89.2B | $105.4B | $111.7B |
| Total Current Assets | — | — | — | — | — |
| Total Assets | $1.2T | $1.2T | $1.2T | $1.2T | $1.4T |
| Current Liabilities | — | — | — | — | — |
| Long-Term Debt | $227.4B | $233.9B | $260.5B | $284.3B | $341.7B |
| Total Liabilities | $1.1T | $1.1T | $1.1T | $1.1T | $1.3T |
| Total Equity | $106.6B | $101.2B | $100.0B | $105.4B | $112.7B |
| Retained Earnings | $89.4B | $94.9B | $98.0B | $105.0B | $115.1B |
Cash Flow (Annual)
Last updated: Jul 31, 2026 4:56am (23d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $34.0B | -$6.4B | -$33.5B | $1.4B | -$17.9B |
| Capital Expenditure | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — |
| Acquisitions (net) | -$2.6B | $0 | $0 | — | — |
| Net Debt Issued / (Repaid) | $20.1B | $37.6B | $13.6B | $28.1B | $39.8B |
| Dividends Paid | -$4.2B | -$5.4B | -$5.8B | -$6.1B | -$6.6B |
| Stock Buybacks | — | — | — | — | — |
| Net Change in Cash | $22.1B | $402.0M | -$38.9B | $16.2B | $6.3B |
Growth Trends (YoY %)
Last updated: Jul 31, 2026 4:56am (23d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -11.0% | +0.9% | +13.7% | +14.5% |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | — | — | — | — |
| Net Income Growth | -26.6% | -17.6% | +47.4% | +25.9% |
| EBITDA Growth | — | — | — | — |
Dividend History (Last 20)
Last updated: Jul 31, 2026 9:08am (23d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-04-30 | $1.00 | — | — | — |
| 2026-01-30 | $1.00 | — | — | — |
| 2025-10-31 | $1.00 | — | — | — |
| 2025-07-31 | $1.00 | — | — | — |
| 2025-04-30 | $0.93 | — | — | — |
| 2025-01-31 | $0.93 | — | — | — |
| 2024-10-31 | $0.93 | — | — | — |
| 2024-07-31 | $0.93 | — | — | — |
| 2024-04-29 | $0.85 | — | — | — |
| 2024-01-30 | $0.85 | — | — | — |
| 2023-10-30 | $0.85 | — | — | — |
| 2023-07-28 | $0.85 | — | — | — |
| 2023-04-28 | $0.78 | — | — | — |
| 2023-01-30 | $0.78 | — | — | — |
| 2022-10-28 | $0.78 | — | — | — |
| 2022-07-28 | $0.78 | — | — | — |
| 2022-04-28 | $0.70 | — | — | — |
| 2022-01-28 | $0.70 | — | — | — |
| 2021-10-28 | $0.70 | — | — | — |
| 2021-07-29 | $0.70 | — | — | — |
Deep Analysis
Narrative Economics
market-narrative step).
Claude Reading
Looking at the raw print first: MS did $65.97B revenue and $16.86B net income in 2025, up from $57.62B/$13.39B in 2024 — that's 14.5% revenue growth and 26% earnings growth, with net margin expanding to 25.6%. Quarterly NI trajectory ($3.08B → $3.19B → $3.71B → $4.32B → $3.54B → $4.61B → $4.40B → $5.57B) shows genuine acceleration into Q1 2026, not a plateau. Trailing four quarters of NI sum to ~$18.1B, meaning the trailing P/E is closer to 18x than the 20.5x annual figure suggests. ROE of 15% is respectable but not extraordinary for a firm whose peers (GS, JPM) print similar or better. The negative $17.9B operating cash flow is normal noise for a broker-dealer (trading asset swings) and should not be read as distress.
Where I diverge from the prior stack: the synthesis verdict of "slight upside" with a $229–247 fair value feels too generous, while the thesis evaluation's -8 score and market-forces "neutral with peak-cycle risk" feel closer to reality. The models are contradicting each other and the DCF-anchored $246 number is almost certainly extrapolating the 36% earnings CAGR forward, which is a garbage-in problem — 2022–2023 were trough IB years, so the CAGR is off a depressed base. Normalize to a mid-cycle $16–17B NI and slap a defensible 15x on it (bank-normal, wealth-premium blended) and you get $240–255B market cap, i.e., $153–163 per share. The market is paying $330B / 20x for a franchise whose sustainable earnings are debatable at $17B. That is not "slight upside" — that is fair-to-full.
The contrarian argument is actually the base case here: MS trades at ~3x book with a 15% ROE, meaning the market is capitalizing the wealth-management transformation at a permanent premium. But three things could break it: (1) fee compression in wealth as passive/RIA competition intensifies — the industry is heading to sub-50bps blended fees; (2) IB/trading normalizes DOWN, not up — the 2025 print may be near-peak given elevated M&A and volatility, and Q1 2026's $5.57B could be the high-water mark; (3) rate cuts compress NII on the ~$340B debt/deposit base. Insider activity reinforces this: six sales versus zero open-market buys in July 2026, with awards being routine grants. Insiders monetizing at $210+ is a mild but real tell. The narrative model correctly flags this as "anchored" and "steady-compounder" — but a steady compounder at 3x book with cyclical earnings mix is priced for a lot to go right.
I dissent from the synthesis's +17% upside call and side with the thesis evaluation and market-forces read. Fair value on normalized earnings is closer to $175–190, not $230–247. The $210 price bakes in continuation of Q1 2026's exceptional print, sustained wealth margin expansion, AND no capital markets mean reversion — a trifecta bet. The 1.9% dividend yield is not enough to underwrite the multiple risk. That said, this is a quality franchise and I'm not calling it a short — the E*Trade integration is real, wealth AUM growth is real, and dividend/buyback capacity is real. But at $210 the risk/reward is asymmetrically to the downside: a re-rating to 15x normalized earnings takes you to ~$155, while further upside requires either the wealth thesis to keep expanding multiples (from already-elevated 3x book) or a full cycle up-leg in IB. I'd want $175 or lower to build a position, or evidence in Q2/Q3 2026 that the $5.57B quarterly NI is a new floor rather than a peak.
GPT Reading
At $210.55, Morgan Stanley is being valued like a high-quality compounder rather than a cyclical capital-markets house, and the raw numbers only partly support that. The business has undeniably rebounded: revenue rose from $50.67B in 2023 to $57.62B in 2024 and $65.97B in 2025, while net income climbed from $9.09B to $13.39B to $16.86B. Quarterly profit progression is also strong, with 2025 net income of $16.86B versus $13.39B in 2024, and the most recent quarter at $5.57B versus $4.32B in the year-ago March quarter, about 29% growth. Net margin in 2025 was 25.6%, which is excellent for a diversified broker-bank. But that earnings recovery has already been capitalized very aggressively: the stock sits at 20.6x earnings, 3.08x book, 5.26x sales, and roughly 8.3x EV/revenue. For a firm with 2021 net income of $15.03B, 2022 of $11.03B, 2023 of $9.09B, and 2025 of $16.86B, that is not a smooth compounding record; it is a cyclical earnings stream now being priced near peak conditions.
The most important disconnect in the data is between quality of franchise and quality of valuation. ROE of 15.0% is good, but not good enough to make 3.1x book feel cheap for a large financial with meaningful market-sensitive businesses. If you invert the current valuation, the market is assuming either sustainably higher ROE ahead or that book value meaningfully understates the earning power of the wealth franchise. Maybe that is partly true, but the provided numbers do not prove it. Equity is $112.65B against $341.68B of debt, and cash is $111.70B; in banks, leverage is normal, but it still means small changes in spreads, deal activity, trading conditions, or credit marks can move earnings materially. The negative operating cash flow of $17.89B is not, by itself, a red flag for a financial institution, but it is a reminder not to treat this like an industrial free-cash-flow machine. I do not think a 1.9% dividend yield and 39.1% payout ratio are enough to bail out buyers if the multiple falls from 20x toward the mid-teens.
What stands out is that the market seems to be rewarding Morgan Stanley for becoming less cyclical at exactly the point the reported earnings look most cyclical-influenced. Net income moved from $3.08B in 2024's June quarter to $3.54B in 2025's June quarter, from $3.19B to $4.61B in September, from $3.71B to $4.40B in December, and then to $5.57B in March 2026. That is a very strong run, but it looks more like favorable operating backdrop and market activity than evidence that cyclicality has been engineered away. If I put a more conservative multiple on current earnings power — say 15x to 17x on $16B-$17B of net income — I get to a valuation range much closer to the current price, not clear upside. On book, even a premium franchise at 2.2x-2.6x book would imply meaningful downside from 3.1x unless ROE expands beyond 15% and stays there. My read is that investors are paying tomorrow’s “durable wealth manager” multiple on today’s still market-dependent earnings base.
The best case against my view is straightforward: the earnings line is not just recovering, it is accelerating, and the premium may be deserved. Revenue grew 14.5% in the latest annual period and earnings nearly 26%; net income has blown past the 2021 level, suggesting the franchise is larger and more profitable than the prior cycle peak. A 15% ROE with a 25.6% net margin is objectively strong, and if wealth and fee-based businesses are now the anchor, then comparing Morgan Stanley to ordinary banks or to its own older valuation range may be too conservative. There is also nothing alarming in insider activity; the sales are small relative to company size and look routine. If 2026 annualized earnings are moving toward roughly $18B-$19B based on the recent quarterly pace, then the current P/E rapidly compresses into the high teens, and the stock could grow into the valuation without requiring multiple expansion.
What would change my mind is evidence that this is not just a cyclical profit spike. If Morgan Stanley can deliver another year of revenue above $68B, sustain quarterly net income around $4.5B-$5.0B even in softer capital-markets conditions, and push ROE toward 17% without leverage creeping up, then the premium to book is easier to defend and I would become constructive above $210. Conversely, if earnings slip back toward the $13B-$14B range or revenue stalls while the stock still commands 18x-20x earnings and 3x book, the market will likely re-rate it toward a less flattering but more normal large-cap financial multiple. I think fair value is below the current price unless the next 12 months prove the new earnings base is genuinely durable.
Grok Reading
The raw numbers show a franchise that has decisively stepped up its earnings power. Annual net income climbed from a $9.09B trough in 2023 to $13.39B in 2024 and $16.86B in 2025, a 36% earnings CAGR against 14% revenue CAGR, with net margins expanding to 25.6%. Trailing four-quarter NI already annualizes near $18.1B ($5.57B + $4.40B + $4.61B + $3.54B), and the most recent print of $5.57B is the strongest quarter in the entire series. At $210.55 the stock trades at 20.6x the 2025 annual and closer to 18.3x that fresher TTM run-rate, with ROE at 15% on $112.65B of equity. Revenue growth of 14.5% year-over-year to $65.97B is real and broad-based enough that the wealth-management mix shift is no longer just a story—it is visible in the margin expansion and the durability of the NI trajectory through rate and volatility swings.
What stands out against the prior models is how cleanly the operating momentum contradicts the cautious “peak-cycle perfection” framing. The valuation synthesis composite at $229–$247 already implies 9–17% upside, yet the thesis score of –8 and the “multiple compression to bank norms” bear case treat the 3.08x P/B and 20x P/E as fragile. Those multiples are elevated versus traditional bank history, but they are being earned by a 25%+ net margin business that is no longer pure capital-markets cyclicality. Negative operating cash flow of –$17.89B looks alarming until one remembers broker-dealer accounting; the balance sheet still carries $111.7B cash against $341.7B debt and a 3.0x debt-to-equity that is structural, not distressed. Insider activity is routine selling into strength, not a signal. The data simply do not support the idea that current earnings are a fluke crest.
The strongest counter-argument is straightforward: capital-markets and advisory revenues remain cyclical, rate cuts and lower volatility will compress trading and IB fees, and a 20x P/E / 3x P/B leaves little cushion if the wealth-management moat proves less capital-light or less sticky than priced. A smart opponent would note that 2021 already delivered $15B of NI at the last peak, that ROA is still only 1.2%, and that the stock sits below sector benchmarks with macro headwinds flagged. They would also point out that the payout ratio of 39% and 1.9% yield are respectable but not defensive enough if earnings mean-revert $3–4B. I weigh this less heavily because the last eight quarters show progressive, not mean-reverting, NI, and the 14% revenue CAGR has already absorbed a full rate cycle without collapsing margins. The re-rating is partially earned; it is not pure narrative.
I would flip to a more cautious stance if two consecutive quarters print NI below $4.0B, if 2026 full-year revenue growth slows below 5%, or if management signals material fee compression or elevated credit costs inside wealth management that push ROE back under 12%. Until then the earnings trajectory and the modest discount to the internal fair-value range dominate.
Big-3 Panel — where each AI stands
Claude — Second Response · overvalued revised
VERDICT: Overvalued at $210 — fair value $180–195 on normalized $16–17B earnings; wait for Q2/Q3 2026 to confirm the $5.57B print is a floor, not a peak, before paying up.
Colleagues' arguments considered. GPT largely converges with my view but frames it as "fair to slightly overvalued" rather than my more aggressive $175-190 target — the difference matters. Grok makes the strongest challenge: the trailing four-quarter NI genuinely annualizes to $18.1B, which drops the effective P/E to ~18.3x, not the 20.6x I anchored on. That's a fair correction to my framing. But Grok then does exactly what I flagged as garbage-in: extrapolates the $5.57B Q1 2026 print forward as run-rate rather than as a possible peak. The sequence $3.08B → $5.57B over eight quarters is not "progressive, not mean-reverting" — it's an eight-quarter uptrend during a period of elevated M&A, strong equity markets, and still-high NII. Calling that "already absorbed a full rate cycle" is generous; rate cuts largely haven't hit yet.
Where I concede ground: my $155 downside anchor at 15x normalized was too punitive if you accept that wealth management genuinely deserves a premium multiple blend. A 16-17x on $16-17B normalized gets you $256-289B market cap, or $163-184/share — so the top of my range ($190) is defensible but the midpoint should probably nudge up to $180-195. Grok's point about the wealth mix shift being "visible in margin expansion" is the real argument, and I underweighted it. The 25.6% net margin is not something a pure capital-markets shop prints.
Where Grok fails to move me: the composite $229-247 fair value still depends on capitalizing peak-quarter earnings at a premium multiple. That's double-counting the cycle. And the insider selling — six sales, zero opens — is dismissed too casually by both colleagues; it's not a smoking gun but it's directionally consistent with insiders viewing $210 as full, not cheap. I'm holding overvalued but tightening the range upward modestly and lowering conviction a notch given the legitimate TTM-vs-annual point.
GPT — Second Response · overvalued revised
VERDICT: Slightly overvalued at $210.55 — fair value is closer to $190-$205, with upside only if $17.5B-$18B earnings and higher-than-15% ROE prove durable through a softer backdrop.
Claude mostly reinforced my original stance, but he sharpened one point I had underweighted: the trailing four-quarter earnings power is already about $18.1B, so the relevant multiple is nearer 18x than the 20.6x based on 2025 alone. That matters, and it weakens the harsher version of the overvaluation case. What did not move me is Grok’s leap from that fresher run-rate to “earned re-rating” without really solving the ROE/PB mismatch. A 15% ROE at ~3.1x book still implies the market is paying a premium usually reserved for either structurally higher returns or much lower cyclicality than the numbers yet prove. The last eight quarters are strong, yes, but they still coincide with a very favorable backdrop for trading, advisory, asset values, and client activity. I also agree with Claude that DCF-style upside built off trough-to-peak CAGR is the wrong anchor here.
So I am revising only in degree, not direction. The better bear case is no longer “this is clearly worth only mid-teens P/E on depressed normalized earnings,” because the current TTM has earned more respect than that. But the better bull case still falls short of making $210 obviously cheap: if I give MS credit for $17.5B-$18.0B sustainable earnings and a premium 16x-17x multiple because the wealth mix is genuinely better than old-cycle Morgan Stanley, I land around roughly fair to slightly rich, not meaningfully undervalued. That pushes my fair value range up modestly from my first pass, but I still think the stock discounts a lot of durability that has not been tested in a softer capital-markets tape. I would need either ROE pushing toward 17% or evidence that $4.5B-$5B quarterly profit holds through weaker conditions before paying comfortably above $210.
Grok — Second Response · overvalued changed direction
VERDICT: Modestly overvalued at $210.55; normalized mid-cycle value sits nearer $180–200 until durability is proven
The colleagues’ normalization math is the argument that lands. I underweighted how much of the 36% earnings CAGR is simply rebound from the 2022–23 IB trough; applying a blended 15–17x to a mid-cycle $16–17 B NI (instead of capitalizing the $18.1 B TTM run-rate at 18–20x) compresses fair value into the $175–200 zone and makes the internal $229–247 composite look like an extrapolation error. Equally persuasive is the ROE-versus-P/B gap both flag: 15 % ROE does not by itself underwrite a permanent 3.08x book multiple for a firm that still carries material capital-markets beta and $342 B of structural leverage. The progressive quarterly prints remain real, yet they have not yet demonstrated a $4.5 B+ floor through softer conditions, so the “earned re-rating” claim is premature.
I therefore revise from modest undervaluation to a more guarded stance. The wealth-management mix shift and margin expansion are genuine and keep me from joining a full short or deep-value call; downside to $155 requires a sharper mean-reversion than the last eight quarters imply. Still, at $210 the market is already discounting continuation of the Q1 2026 peak plus further multiple support. Risk/reward is now asymmetric until either two more quarters confirm the new earnings base or the shares pull back toward $185–195.
Advanced Analysis Forensic deep-dive · separate lenses
Revenue has grown from 56.4B in 2021 to 66.0B in 2025 (roughly 4% CAGR), with net income rebounding from a 2023 trough of 9.1B to 16.9B in 2025 — the highest of the five-year window. Diluted shares shrank from 1.87B to 1.65B, a -3.1% CAGR, meaning per-share earnings compounded faster than headline earnings. SBC at 2.9% of revenue is fully absorbed by buybacks. This is the profile of a mature earner returning capital.
Verify before trusting this (6)
- Segment mix and trend: wealth management fee-based AUM growth vs. trading revenue cyclicality
- CET1 ratio and regulatory capital cushion vs. requirements
- Reconcile reported OCF swings to trading inventory / repo flows in 10-K cash flow detail
- Buyback authorization remaining and pace vs. earnings
- Any material litigation reserves or level-3 asset concentration
- Concentration in prime brokerage clients (e.g., post-Archegos risk controls)
The composite fair value of $229 and signal-adjusted $246.86 imply 8-17% upside, but both lean on an anchored-PE method applied to what the quality lens explicitly flags as cyclical earnings at or near a peak. Capitalizing peak EPS at a normal multiple systematically overstates deserved value for a capital-markets-heavy bank, so I haircut the FV toward the low $220s before comparing to price. Against that, $210.55 is within a normal band of fair, not a discount worth pounding the table on. The earnings-quality signal (-1, weak) reinforces the haircut - even if several red flags are bank-accounting artifacts, the direction of travel on deserved value is down, not up. What is priced in: continued wealth management growth, decent capital markets activity, and buybacks (share count CAGR -3.1%) supporting per-share compounding. What is NOT priced in as a bargain: any rerating from here needs either sustained above-cycle IB/trading or multiple expansion, both of which are hopes, not margins of safety. This is a good business the market understands, changing hands near its deserved price.
Verify before trusting this (4)
- Wealth management fee-based asset growth and net new asset trends in the latest 10-Q
- Institutional Securities revenue mix - how much of recent EPS is trading vs advisory, to gauge cyclicality of the earnings base
- Forward guidance/commentary on IB pipeline and expense ratios
- Any one-time integration or legal charges distorting the anchored EPS input
The macro tape is broadly neutral with a slight tailwind (VIX 16, S&P near highs), which for a 1.22-beta capital markets name is a mild positive - MS earns off deal flow, trading volumes, and wealth AUM, all of which prefer calm-but-not-sleepy tapes. But the 10y at 4.68% and a stretched market PE at 26.2 create a low-grade headwind for financials broadly, and the active bear whisper is that eventual rate cuts and volatility compression will squeeze trading and NIM. Narrative intensity is minimal and durability is high - this is a boring steady-compounder story with low cult coefficient, meaning sentiment is neither juicing nor punishing the stock. It just sits there. That is a Balanced setup by construction. The news flow is genuinely mixed: a $13B advisor team defection from Graystone to Merrill is a real negative sentiment datapoint for the wealth franchise (the exact bear thesis - fee/margin pressure and advisor mobility post-E*Trade), while the routine dividend confirmation and lead-arranger role on the Morton Salt $3.2B TLB are neutral-to-positive reminders that the capital markets engine is functioning. There is no dominant force here; the stock trades on its own fundamentals with only ordinary sentiment crosswinds.
Verify before trusting this (4)
- Whether more large advisor teams follow the Graystone defection to Merrill or elsewhere
- Analyst target revisions post next print - watch for wealth margin commentary
- Fed path repricing - a dovish shift would pressure MS trading revenue narrative
- VIX regime shift - a spike above 22 would flip the tape read for capital markets names
This lens hasn't been run for this ticker yet.
When we made this prediction on Aug 1, 2026, MS was $210.55. We expect it to be $227.00 by Feb 2027, and we consider it great value under $180.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 1, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.